tazobactam has been researched along with Disease Models, Animal in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Canovas, J; Chau, F; Fantin, B; Le Monnier, A; Lefort, A; Petitjean, G | 1 |
| Monogue, ML; Nicolau, DP; Nizet, V; Sakoulas, G | 1 |
| Agudelo, M; Rodriguez, CA; Vesga, O; Zuluaga, AF | 1 |
| Calcinari, A; Casteletti, S; Cirioni, O; Ghiselli, R; Giacometti, A; Guerrieri, M; Kamysz, E; Kamysz, W; Orlando, F; Rimini, M; Silvestri, C; Tocchini, M | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Kaygusuz, A | 1 |
| Akgün, H; Erkiliç, K; Esel, D; Evereklioglu, C; Göktas, S; Ozkiris, A | 1 |
| Jacobus, NV; Kuck, NA; Petersen, PJ; Tally, FP; Testa, RT; Weiss, WJ | 1 |
| Appavu, SK | 1 |
| Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Kamysz, E; Kamysz, W; Mocchegiani, F; Orlando, F; Riva, A; Rocchi, M; Saba, V; Scalise, G; Silvestri, C | 1 |
| Abbruzzetti, A; Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C | 1 |
| Decazes, JM; Gutmann, L; Kitzis, MD; Leleu, G; Vallois, JM | 1 |
| Eliopoulos, GM; Moellering, RC; Pefanis, A; Thauvin-Eliopoulos, C | 1 |
13 other study(ies) available for tazobactam and Disease Models, Animal
| Article | Year |
|---|---|
Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cephalosporins; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Imipenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Tazobactam | 2020 |
Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Lung; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Thigh | 2018 |
Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Disease Models, Animal; Enterobacter cloacae; Humans; Mesothelin; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 2015 |
Protective effect of citropin 1.1 and tazobactam-piperacillin against oxidative damage and lethality in mice models of gram-negative sepsis.
Topics: Amphibian Proteins; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Penicillanic Acid; Piperacillin; Tazobactam | 2011 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
Infecting one animal with two different strains of the same bacteria may cause misleading results.
Topics: Abscess; Animals; Disease Models, Animal; Enzyme Inhibitors; Hindlimb; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Reproducibility of Results; Tazobactam | 2002 |
The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tazobactam; Treatment Outcome; Vitreous Body | 2005 |
Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Gastric Juice; Hydrogen-Ion Concentration; Mice; Microbial Sensitivity Tests; Mucins; Penicillanic Acid; Piperacillin; Swine; Tazobactam | 1989 |
Can the ravages of uncontrolled systemic inflammatory response be regulated by amphibian antimicrobial peptides?
Topics: Amphibian Proteins; Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacterial Translocation; Bile Ducts; Disease Models, Animal; Endotoxins; Jaundice, Obstructive; Magainins; Penicillanic Acid; Peptides; Piperacillin; Rats; Tazobactam; Xenopus Proteins | 2006 |
Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; DNA-Binding Proteins; Drug Synergism; Enterococcus faecalis; Escherichia coli; Granulocyte Colony-Stimulating Factor; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Peptides, Cyclic; Peritonitis; Piperacillin; Survival Rate; Tazobactam; Time Factors | 2008 |
Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.
Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enterococcus faecalis; Escherichia coli; Escherichia coli Infections; Gram-Positive Bacterial Infections; Male; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Rats; Rats, Wistar; Shock, Septic; Tazobactam; Treatment Outcome | 2008 |
Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
Topics: Animals; beta-Lactamase Inhibitors; beta-Lactamases; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Klebsiella Infections; Klebsiella pneumoniae; Meningitis, Bacterial; Penicillanic Acid; Piperacillin; Rabbits; Tazobactam | 1994 |
Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis.
Topics: Abdomen; Abscess; Animals; Bacteroides fragilis; Bacteroides Infections; Ceftriaxone; Disease Models, Animal; Drug Therapy, Combination; Male; Penicillanic Acid; Peritoneal Diseases; Rats; Rats, Sprague-Dawley; Tazobactam | 1993 |